Cogent Biosciences (COGT) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $29.52, +0.03% vs the prior close of $29.51.
- Volume 2.78M shares, 1.4x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
COGT ends flat (+0.0%) to $29.52, 3 up days in a row. Closed at $29.52, +0.03% vs the prior close of $29.51. Day range $28.77–$29.97, opened at $29.47.
COGT daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — COGT ends flat (+0.0%) to $29.52, 3 up days in a row
- Closed at $29.52, +0.03% vs the prior close of $29.51. Day range $28.77–$29.97, opened at $29.47.
- Volume was 2.78M shares, 1.4x its 50-day average of 1.95M.
- Price is -12.8% vs its 50-day average ($33.85) and -17.8% vs its 200-day average ($35.91).
- 52-week range $13.78–$43.73; today's close sits at 53% of that range, 32.5% below the 52-week high.
- That makes 3 straight gains.
Oct 15, 2026 — COGT jumps 4.8% to $29.51
- Closed at $29.51, +4.83% vs the prior close of $28.15. Day range $28.33–$29.78, opened at $28.33.
- Volume was 3.04M shares, 1.6x its 50-day average of 1.93M.
- Price is -13.4% vs its 50-day average ($34.09) and -17.9% vs its 200-day average ($35.95).
- 52-week range $13.78–$43.73; today's close sits at 53% of that range, 32.5% below the 52-week high.
Oct 14, 2026 — COGT ends flat (+0.2%) to $28.15
- Closed at $28.15, +0.21% vs the prior close of $28.09. Day range $27.74–$29.05, opened at $27.93.
- Volume was 2.30M shares, 1.2x its 50-day average of 1.98M.
- Price is -18.0% vs its 50-day average ($34.35) and -21.8% vs its 200-day average ($35.99).
- 52-week range $13.78–$43.73; today's close sits at 48% of that range, 35.6% below the 52-week high.
Oct 13, 2026 — COGT slides 5.7% to $28.09, a 6-month low
- Closed at $28.09, -5.67% vs the prior close of $29.78. Day range $27.85–$29.46, opened at $29.46.
- Volume was 2.99M shares, 1.5x its 50-day average of 1.95M.
- Price is -18.9% vs its 50-day average ($34.64) and -22.1% vs its 200-day average ($36.04).
- 52-week range $13.78–$43.73; today's close sits at 48% of that range, 35.8% below the 52-week high.
Oct 12, 2026 — COGT slides 3.9% to $29.78, a 6-month low
- Closed at $29.78, -3.94% vs the prior close of $31.00. Day range $29.63–$31.07, opened at $30.81.
- Volume was 1.86M shares, 1.0x its 50-day average of 1.94M.
- Price is -14.6% vs its 50-day average ($34.86) and -17.5% vs its 200-day average ($36.10).
- 52-week range $13.78–$43.73; today's close sits at 53% of that range, 31.9% below the 52-week high.
Oct 9, 2026 — COGT jumps 3.1% to $31.00
- Closed at $31.00, +3.06% vs the prior close of $30.08. Day range $29.90–$31.03, opened at $29.98.
- Volume was 2.52M shares, 1.3x its 50-day average of 1.93M.
- Price is -11.5% vs its 50-day average ($35.04) and -14.3% vs its 200-day average ($36.15).
- 52-week range $13.78–$43.73; today's close sits at 57% of that range, 29.1% below the 52-week high.
Oct 8, 2026 — COGT ends flat (-0.2%) to $30.08, a 6-month low on 1.9x normal volume
- Closed at $30.08, -0.20% vs the prior close of $30.14. Day range $28.69–$30.66, opened at $29.71.
- Volume was 3.64M shares, 1.9x its 50-day average of 1.88M — unusually heavy trading.
- Price is -14.7% vs its 50-day average ($35.25) and -16.9% vs its 200-day average ($36.20).
- 52-week range $13.78–$43.73; today's close sits at 54% of that range, 31.2% below the 52-week high.
- That makes 6 straight losses.
Oct 7, 2026 — COGT dips 0.8% to $30.14, a 6-month low, 5 down days in a row
- Closed at $30.14, -0.79% vs the prior close of $30.38. Day range $29.88–$30.43, opened at $30.05.
- Volume was 1.26M shares, 0.7x its 50-day average of 1.87M.
- Price is -14.9% vs its 50-day average ($35.44) and -16.8% vs its 200-day average ($36.24).
- 52-week range $13.78–$43.73; today's close sits at 55% of that range, 31.1% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — COGT dips 1.6% to $30.38, a 6-month low, 4 down days in a row
- Closed at $30.38, -1.59% vs the prior close of $30.87. Day range $29.70–$31.17, opened at $31.17.
- Volume was 2.38M shares, 1.3x its 50-day average of 1.85M.
- Price is -14.8% vs its 50-day average ($35.65) and -16.3% vs its 200-day average ($36.28).
- 52-week range $13.78–$43.73; today's close sits at 55% of that range, 30.5% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — COGT dips 0.5% to $30.87, a 6-month low, 3 down days in a row
- Closed at $30.87, -0.48% vs the prior close of $31.02. Day range $29.93–$31.37, opened at $31.26.
- Volume was 1.79M shares, 1.0x its 50-day average of 1.85M.
- Price is -13.9% vs its 50-day average ($35.85) and -15.0% vs its 200-day average ($36.33).
- 52-week range $13.78–$43.73; today's close sits at 57% of that range, 29.4% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — COGT dips 1.8% to $31.02, a 3-month low
- Closed at $31.02, -1.80% vs the prior close of $31.59. Day range $30.85–$32.29, opened at $32.12.
- Volume was 1.17M shares, 0.6x its 50-day average of 1.89M.
- Price is -13.9% vs its 50-day average ($36.02) and -14.7% vs its 200-day average ($36.37).
- 52-week range $13.78–$43.73; today's close sits at 58% of that range, 29.1% below the 52-week high.
COGT latest news & SEC filings
Every SEC filing by or about COGT in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Aug 31, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Morris Arlene sold 3,161 shares at $37.54 (≈$118.66K) on Aug 27, 2026
- Morris Arlene sold 42,349 shares at $37.09 (≈$1.57M) on Aug 27, 2026
- Morris Arlene sold 3,161 shares at $37.54 (≈$118.66K) on Aug 27, 2026
- Morris Arlene sold 42,349 shares at $37.09 (≈$1.57M) on Aug 27, 2026
- Morris Arlene sold 3,161 shares at $37.54 (≈$118.66K) on Aug 27, 2026
- Morris Arlene sold 42,349 shares at $37.09 (≈$1.57M) on Aug 27, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 27, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 10, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 10, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$96.41M (prior year -$73.53M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.52 (prior year -$0.53) (loss narrowed vs Jun 30, 2025)
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 31, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 27, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade COGT
- Last results release: Aug 10, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Feb 17, 2026, Nov 3, 2025. Based on that rhythm, the next report is likely around Nov 9, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.86% (largest 5.7%).
- Liquidity: about 2.33M shares (≈$68.88M) trade per day on average.
- 52-week position: $29.52 vs a range of $13.78–$43.73 (53% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Arlene Morris sold 3,161 shares on Aug 27, 2026.
- Latest filings: 8-K Sep 2, 2026; 8-K Aug 10, 2026; 10-Q Aug 10, 2026.
- Share count: 173.52M shares outstanding (Aug 6, 2026), +24.2% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
COGT market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 29.47 | 29.97 | 28.77 | 29.52 | 2.78M |
| Oct 15, 2026 | 28.33 | 29.78 | 28.33 | 29.51 | 3.04M |
| Oct 14, 2026 | 27.93 | 29.05 | 27.74 | 28.15 | 2.30M |
| Oct 13, 2026 | 29.46 | 29.46 | 27.85 | 28.09 | 2.99M |
| Oct 12, 2026 | 30.81 | 31.07 | 29.63 | 29.78 | 1.86M |
| Oct 9, 2026 | 29.98 | 31.03 | 29.90 | 31.00 | 2.52M |
| Oct 8, 2026 | 29.71 | 30.66 | 28.69 | 30.08 | 3.64M |
| Oct 7, 2026 | 30.05 | 30.43 | 29.88 | 30.14 | 1.26M |
| Oct 6, 2026 | 31.17 | 31.17 | 29.70 | 30.38 | 2.38M |
| Oct 5, 2026 | 31.26 | 31.37 | 29.93 | 30.87 | 1.79M |
| Oct 2, 2026 | 32.12 | 32.29 | 30.85 | 31.02 | 1.17M |
| Oct 1, 2026 | 32.02 | 32.57 | 31.52 | 31.59 | 1.70M |
| Sep 30, 2026 | 31.74 | 32.76 | 31.49 | 32.02 | 1.96M |
| Sep 29, 2026 | 31.76 | 32.12 | 31.32 | 31.66 | 1.70M |
| Sep 28, 2026 | 32.00 | 32.20 | 31.23 | 31.86 | 2.21M |
| Sep 25, 2026 | 31.55 | 32.71 | 31.05 | 32.31 | 2.98M |
| Sep 24, 2026 | 31.21 | 31.95 | 30.35 | 31.43 | 2.59M |
| Sep 23, 2026 | 32.62 | 32.85 | 30.88 | 31.41 | 2.33M |
| Sep 22, 2026 | 32.23 | 32.85 | 32.06 | 32.63 | 2.04M |
| Sep 21, 2026 | 31.97 | 32.51 | 31.41 | 32.00 | 3.42M |
About Cogent Biosciences
Cogent Biosciences (COGT) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WALTHAM, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1622229.
COGT board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Christopher W. Cain | Director | Jun 11, 2026 |
| Funds Management Llc Fairmount | Director | Mar 31, 2026 |
| Karen Jean Ferrante | Director | Jul 6, 2026 |
| Peter Evan Harwin | Director | Jun 11, 2026 |
| Arlene Morris | Director | Aug 31, 2026 |
| Andrew R Robbins | President and CEO | May 21, 2026 |
| Matthew Ros | Director | Jun 11, 2026 |
| Todd Shegog | Director | Jun 11, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| John L. Green | Chief Financial Officer | Dec 30, 2025 |
| Evan Kearns | Chief Legal Officer | Dec 30, 2025 |
| Cole Pinnow | Chief Commercial Officer | Dec 19, 2025 |
| Andrew R Robbins | President and CEO | May 21, 2026 |
| John Edward Robinson | Chief Scientific Officer | Dec 30, 2025 |
| Jessica Sachs | Chief Medical Officer | Dec 30, 2025 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 27, 2026 | Arlene Morris | Sale | 3,161 | $37.54 |
| Aug 27, 2026 | Arlene Morris | Sale | 42,349 | $37.09 |
| Aug 27, 2026 | Arlene Morris | Sale | 3,161 | $37.54 |
| Aug 27, 2026 | Arlene Morris | Sale | 42,349 | $37.09 |
| Aug 27, 2026 | Arlene Morris | Sale | 3,161 | $37.54 |
| Aug 27, 2026 | Arlene Morris | Sale | 42,349 | $37.09 |
| Aug 27, 2026 | Arlene Morris | Sale | 3,161 | $37.54 |
| Aug 27, 2026 | Arlene Morris | Sale | 42,349 | $37.09 |
| Mar 31, 2026 | Funds Management Llc Fairmount | Sale | 7,000,000 | $34.66 |
| Mar 31, 2026 | Funds Management Llc Fairmount | Sale | 7,000,000 | $34.66 |
| Mar 31, 2026 | Funds Management Llc Fairmount | Sale | 7,000,000 | $34.66 |
| Mar 31, 2026 | Funds Management Llc Fairmount | Sale | 7,000,000 | $34.66 |
| Jan 22, 2026 | Funds Management Llc Fairmount | Sale | 3,500,000 | $36.40 |
| Jan 22, 2026 | Funds Management Llc Fairmount | Sale | 3,500,000 | $36.40 |
| Jan 22, 2026 | Funds Management Llc Fairmount | Sale | 3,500,000 | $36.40 |
COGT financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-328.94M | -2.16 | $-264.44M |
| Dec 31, 2024 | — | $-255.86M | -1.94 | $-207.79M |
| Dec 31, 2023 | — | $-192.41M | -1.94 | $-153.62M |
| Dec 31, 2022 | — | $-140.24M | -1.73 | $-118.64M |
| Dec 31, 2021 | — | $-72.27M | -1.87 | $-58.76M |
Latest balance sheet: total assets $834.55M, total liabilities $302.16M, cash $181.17M (as of Jun 30, 2026).
COGT earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 10, 2026 | 8-K Item 2.02 (results) | $41.53 |
| May 5, 2026 | 8-K Item 2.02 (results) | $36.98 |
| Feb 17, 2026 | 8-K Item 2.02 (results) | $37.62 |
| Nov 3, 2025 | 8-K Item 2.02 (results) | $15.50 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $11.36 |
| Jul 10, 2025 | 8-K Item 2.02 (results) | $10.85 |
| May 6, 2025 | 8-K Item 2.02 (results) | $4.70 |
| Feb 25, 2025 | 8-K Item 2.02 (results) | $6.99 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $10.38 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Feb 26, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on COGT
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.